EUVIMEDEUVIMED entdecken
Crossref

Questionnaire Survey on the Current Status of Advanced Therapy for Inflammatory Bowel Disease in Asia

Yosuke Toya, Akiko Shiotani, Shoko Ono, Yutaka Saito, Mitsushige Sugimoto, Yuji Naito, Sachiyo Nomura, Osamu Handa, Tadakazu Hisamatsu, Mitsuhiro Fujishiro, Takahisa Matsuda, Yoshinori Morita und 9 weitere

Digestion · 2025

DOI: 10.1159/000549339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestion, 2025. Verfasst von Yosuke Toya und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Gastrointestinal Agents, Practice Patterns, Physicians'. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The incidence of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is increasing rapidly worldwide. Although multiple advanced therapies are now available, selecting the optimal treatment remains challenging due to the expanding options and diverse healthcare systems.

Methods

We conducted a questionnaire survey among physicians in nine Asian countries prior to the 18th International Gastrointestinal Consensus Symposium (IGICS) to assess the current status of advanced therapies for IBD. The survey included questions regarding therapeutic agent selection, biomarkers, and imaging modalities for monitoring.

Results

Of the 210 respondents, 173 physicians treating IBD were analyzed. Anti-TNFα antibodies remain the most commonly selected advanced therapy for both UC and CD. Elderly patients with UC were more likely to receive anti-α4β7-integrin antibodies or anti-IL-12/23p40 monoclonal antibodies, reflecting safety considerations. Janus kinase inhibitors were used more frequently as a second-line option in severe cases. Comorbidities, drug costs, and lifestyle factors also influenced treatment choice. CRP is the most common biomarker used for monitoring, and endoscopy is the most frequently used imaging modality.

Conclusion

This questionnaire survey revealed the current status of advanced therapies for IBD in nine Asian countries and regions. Region-specific evidence-based algorithms for selecting advanced therapies for IBD should be established.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseGastrointestinal AgentsPractice Patterns, Physicians'Inflammatory Bowel DiseasesHumansAsiaSurveys and QuestionnairesAntibodies, MonoclonalJanus Kinase InhibitorsBiomarkersTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

Advanced therapyAsiaInflammatory bowel diseaseQuestionnaire survey

Substanzen

Gastrointestinal AgentsAntibodies, MonoclonalJanus Kinase InhibitorsBiomarkersTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan.
  • Department of Gastroenterology and Hepatology, Kawasaki Medical School, Okayama, Japan.
  • Department of Gastroenterology, Hokkaido University Hospital, Sapporo, Japan.
  • Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
  • Research Center for GLOBAL and LOCAL Infectious Disease, Oita University, Oita, Japan.
  • Department of Human Immunology and Nutrition Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Zitieren

APA

Toya, Y., Shiotani, A., Ono, S., Saito, Y., Sugimoto, M., Naito, Y., Nomura, S., Handa, O., Hisamatsu, T., Fujishiro, M., Matsuda, T., Morita, Y., Yahagi, N., Chan, F. K. L., Ang, T. L., Abdullah, M., Tablante, M. C., Prachayakul, V., Li, B., …, & Matsumoto, T. (2025). Questionnaire Survey on the Current Status of Advanced Therapy for Inflammatory Bowel Disease in Asia. Digestion. https://doi.org/10.1159/000549339

Vancouver

Toya Y, Shiotani A, Ono S, Saito Y, Sugimoto M, Naito Y, et al. Questionnaire Survey on the Current Status of Advanced Therapy for Inflammatory Bowel Disease in Asia. Digestion. 2025. doi:10.1159/000549339

BibTeX
@article{Toya2025,
  author = {Toya, Yosuke and Shiotani, Akiko and Ono, Shoko and Saito, Yutaka and Sugimoto, Mitsushige and Naito, Yuji and Nomura, Sachiyo and Handa, Osamu and Hisamatsu, Tadakazu and Fujishiro, Mitsuhiro and Matsuda, Takahisa and Morita, Yoshinori and Yahagi, Naohisa and Chan, Francis K L and Ang, Tiing Leong and Abdullah, Murdani and Tablante, Maria Carla and Prachayakul, Varayu and Li, Baiwen and Jung, Hwoon-Yong and Matsumoto, Takayuki},
  title = {Questionnaire Survey on the Current Status of Advanced Therapy for Inflammatory Bowel Disease in Asia},
  journal = {Digestion},
  year = {2025},
  doi = {10.1159/000549339}
}
Kostenlos starten →